Regulus Therapeutics Inc. (NASDAQ:RGLS) saw strong trading volume on Monday . 1,186,142 shares traded hands during mid-day trading, an increase of 42% from the previous session’s volume of 838,206 shares.The stock last traded at $1.36 and had previously closed at $1.31.

A number of brokerages have commented on RGLS. ValuEngine downgraded shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research report on Monday, June 12th. Wedbush restated an “ourperform” rating and set a $6.00 price objective on shares of Regulus Therapeutics in a research report on Tuesday, June 13th. Finally, Chardan Capital cut their price objective on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, June 13th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $3.63.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million.

In other Regulus Therapeutics news, CFO Daniel R. Chevallard purchased 54,945 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were purchased at an average cost of $0.91 per share, for a total transaction of $49,999.95. Following the completion of the transaction, the chief financial officer now owns 59,415 shares in the company, valued at $54,067.65. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William H. Rastetter purchased 274,725 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was acquired at an average price of $0.91 per share, for a total transaction of $249,999.75. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 549,450 shares of company stock worth $500,000. 4.80% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the business. Teachers Advisors LLC raised its position in Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after acquiring an additional 9,804 shares in the last quarter. Quantitative Investment Management LLC bought a new stake in Regulus Therapeutics in the second quarter worth about $103,000. Tudor Investment Corp ET AL raised its position in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after acquiring an additional 61,373 shares in the last quarter. GSA Capital Partners LLP bought a new stake in Regulus Therapeutics in the second quarter worth about $139,000. Finally, LMR Partners LLP bought a new stake in Regulus Therapeutics in the second quarter worth about $164,000. Hedge funds and other institutional investors own 21.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Regulus Therapeutics Inc. (RGLS) Sees Large Volume Increase” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/25/regulus-therapeutics-inc-rgls-sees-large-volume-increase.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.